Ligelizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ligelizumab
Accession Number
DB11856
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Ligelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma, and Atopic Dermatitis, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
QGE031
Categories
UNII
L8LE0L691T
CAS number
1322627-61-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Ligelizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Ligelizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ligelizumab.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ligelizumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ligelizumab.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ligelizumab.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Ligelizumab.
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Ligelizumab.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ligelizumab.
BelimumabThe risk or severity of adverse effects can be increased when Ligelizumab is combined with Belimumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911250
Wikipedia
Ligelizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceAllergies1
1, 2CompletedTreatmentAsthma, Allergic1
2Active Not RecruitingTreatmentChronic Spontaneous Urticaria1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentAtopic Dermatitis (AD)1
2CompletedTreatmentChronic Spontaneous Urticaria1
2Not Yet RecruitingTreatmentChronic Spontaneous Urticaria1
2TerminatedTreatmentAsthma Bronchial2
2TerminatedTreatmentBullous Pemphigoid (BP)1
2WithdrawnTreatmentPeanut Allergies1
3Not Yet RecruitingTreatmentChronic Spontaneous Urticaria2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:54 / Updated on October 01, 2018 15:05